Duvelisib for the treatment of chronic lymphocytic leukemia.
Sign Up to like & getrecommendations! Published in 2020 at "Expert opinion on pharmacotherapy"
DOI: 10.1080/14656566.2020.1751123
Abstract: Introduction: Duvelisib, a first in class, oral, dual PI3 k-delta/gamma inhibitor recently received FDA approval for previously treated CLL (chronic lymphocytic leukemia)/SLL (small lymphocytic lymphoma) and follicular lymphoma. Data coming from the phase III 'DUO' trial,… read more here.
Keywords: lymphocytic leukemia; duvelisib treatment; treatment; chronic lymphocytic ... See more keywords
Abstract 663: The dual PI3K-δ/PI3K-γ inhibitor duvelisib inhibits signaling and proliferation of solid tumor cells expressing PI3K-δ and/or PI3K-γ
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-663
Abstract: Duvelisib is an oral, dual PI3K-δ,γ inhibitor that is FDA-approved for treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and follicular lymphoma (FL) following ≥2 prior systemic therapies. In addition to targeting malignant B… read more here.
Keywords: pi3k; cell lines; pi3k pi3k; cell ... See more keywords
Duvelisib for CLL/SLL and Follicular Non-Hodgkin Lymphoma.
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood.2019001795
Abstract: Chronic lymphocytic leukemia (CLL/SLL) and follicular lymphoma (FL) represent indolent malignancies characterized by multiple episodes of relapse. Therapy has centered on agents that largely target the B-cell receptor pathway. Duvelisib is a second generation oral… read more here.
Keywords: lymphoma; sll follicular; cll sll; sll ... See more keywords